Session » Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

Date: Sunday, November 5, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 578

Added Value of Biomarkers Compared to Routine Clinical Parameters for the Prediction of Radiographic Spinal Progression in Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 638

Are There Clinical Demographic or Subclinical Ultrasonographic Data That Can Predict Flare in Psoriatic Arthritis Patients during a Phase of Minimal Disease Activity after Spacing of Anti-TNF Blockers Injections?

9:00AM-11:00AM: Abstract Number: 583

Associations of Changes of Radiographic Disease and Spinal Mobility Measures in Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 610

Baseline Structural Damage Predicts Response to Abatacept in Patients with Psoriatic Arthritis: A Post Hoc Analysis from a Phase III Study

9:00AM-11:00AM: Abstract Number: 609

Body Mass Index Does Not Influence the Efficacy of Subcutaneous Abatacept in Patients with Psa: Results from a Phase III Trial

9:00AM-11:00AM: Abstract Number: 603

Characterization of Clinical Benefits in Subjects Classified As ACR20 Non-Responders at Week 104 of Apremilast Treatment: Subanalysis of 3 Long-Term, Phase III Trials

9:00AM-11:00AM: Abstract Number: 579

Circulating MiR-145 As a Marker of Therapeutic Response to Anti-TNF Therapy in Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 639

Clinical and Sonographic Analysis of Patients with Psoriasis without Musculoskeletal Complaints. Preeliminary Results of a Prospective Study: The PRE-Psa Cohort

9:00AM-11:00AM: Abstract Number: 617

Comparing Tofacitinib Safety Profile in Patients with Psoriatic Arthritis in Clinical Studies with Real-World Data

9:00AM-11:00AM: Abstract Number: 604

Consistent Safety Profile with up to 4 Years of Apremilast Treatment: Analysis of Data from 1,493 Subjects with Psoriatic Arthritis in 3 Large, Phase III, Long-Term Studies

9:00AM-11:00AM: Abstract Number: 587

Detection of Structural Lesions on T1 Weighted MRI Versus Radiography of the Sacroiliac Joints in Early Axial Spa: 2-Year Data

9:00AM-11:00AM: Abstract Number: 581

Diagnostic Value of Anti-CD74 Antibodies in Early Axial Spondyloarthritis: Data from the Spondyloarthritis Caught Early (SPACE) Cohort

9:00AM-11:00AM: Abstract Number: 636

Effect of Adding MTX to TNF Inhibitors on Joint Severity Indices and Skin Scores in Psoriatic Arthritis: A Post-Hoc Meta-Analysis of Randomized, Controlled Trials

9:00AM-11:00AM: Abstract Number: 613

Effect of Tofacitinib on Efficacy and Patient-Reported Outcomes in Psoriasis Patients with Baseline Psoriatic Arthritis: A Pooled Analysis of 2 Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 596

Effect of Tofacitinib on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis: Results from 2 Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 614

Effect of Tofacitinib on Reducing Pain in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 611

Effectiveness of Early Adalimumab Therapy in Psoriatic Arthritis Patients from Reuma.Pt

9:00AM-11:00AM: Abstract Number: 630

Effects of Intravenous Golimumab, an Anti-Tnfα Monoclonal Antibody, on Mental and Physical Functioning and Health-Related Quality of Life in Active Psoriatic Arthritis: 24-Week Results of a Phase 3 Trial

9:00AM-11:00AM: Abstract Number: 627

Efficacy and Safety of Apremilast through 104 Weeks in Subjects with Moderate to Severe Psoriasis Randomized to Placebo, Apremilast, or Etanercept Who Continued on or Switched to Apremilast after Week 16 in a Phase 3b Study

9:00AM-11:00AM: Abstract Number: 615

Efficacy of Tofacitinib By Background Methotrexate Dose in Patients with Psoriatic Arthritis: A Post Hoc Analysis of Pooled Data from 2 Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 598

Efficacy of Ustekinumab in Psoriatic Arthritis Patients By Prior Treatment Exposure and Disease Duration

9:00AM-11:00AM: Abstract Number: 589

Erosions at the Sacroiliac Joints and Fatty Lesions at the Spine Are the Most Discriminant Lesions for Recent Onset Axial Spondyloarthritis Recognition

9:00AM-11:00AM: Abstract Number: 584

Factors Associated with the “Bamboo Spine” Phenotype – Data from the Comospa Study

9:00AM-11:00AM: Abstract Number: 585

Frequencies of Ligament Ossification in Patients with Ankylosing Spondylitis According to Several Ligaments Around Spine By Whole Spine CT Scan

9:00AM-11:00AM: Abstract Number: 594

Imaging Biomarkers in Crohn’s Associated Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 595

Improved Patient-Reported Outcomes in Psoriatic Arthritis Patients Treated with Abatacept: Results from a Phase III Trial

9:00AM-11:00AM: Abstract Number: 633

Improvement of Joint Inflammation As Assessed By MRI and Power Doppler Ultrasound (PDUS) in an Open Label Study in Patients with Active Psoriatic Arthritis Treated with Secukinumab.

9:00AM-11:00AM: Abstract Number: 602

Improvements in Work Productivity with up to 104 Weeks of Apremilast Monotherapy: Results from a Phase 3b, Randomized, Controlled Study in Biologic-NaïVe Subjects with Active Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 591

Inflammation on MRI of Spine and Sacroiliac Joints Is Highly Predictive of Structural Damage in Axial Spondyloarthritis: The 5 Years Data of the DESIR Cohort

9:00AM-11:00AM: Abstract Number: 588

Inflammatory Lesions of the Sacroiliac Joints, but Not of the Spine, Are of High Utility for Recent Onset Axial Spondyloarthritis Recognition

9:00AM-11:00AM: Abstract Number: 619

Integrated Efficacy Analysis of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 628

Integrated Efficacy Results from Two Phase 3 Trials of Ixekizumab for the Treatment of Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 616

Integrated Safety Summary of Tofacitinib in Psoriatic Arthritis Clinical Studies

9:00AM-11:00AM: Abstract Number: 634

International League of Associations for Rheumatology. Systematic Review of the Literature to Inform Treatment Recommendations for Psoriatic Arthritis in Resource-Poor Countries

9:00AM-11:00AM: Abstract Number: 599

Intravenous Golimumab in Adult Patients with Active Psoriatic Arthritis: Efficacy and Safety through Week 24

9:00AM-11:00AM: Abstract Number: 629

Is Earlier Golimumab Treatment Initiation in Psa and As Patients Associated with Improved Outcomes?

9:00AM-11:00AM: Abstract Number: 640

Is There a Relationship between Spondyloarthritis and Periodontitis? a Case-Control Study

9:00AM-11:00AM: Abstract Number: 605

Ixekizumab Exhibits a Favorable Safety Profile during 24 Weeks of Treatment in Subjects with Active Psoriatic Arthritis: Integrated Safety Analysis of Two Randomized, Placebo Controlled, Phase III Clinical Trials

9:00AM-11:00AM: Abstract Number: 597

Ixekizumab Improves Patient-Reported Outcomes through 52 Weeks in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to Tumor Necrosis Factor-Inhibitors

9:00AM-11:00AM: Abstract Number: 624

Ixekizumab Provides Sustained Improvement in Signs and Symptoms in Patients with Active Psoriatic Arthritis: Two Year Results from a Phase 3 Trial

9:00AM-11:00AM: Abstract Number: 601

Long-Term (4-Year) Efficacy and Safety of Apremilast Monotherapy in DMARD-Naive Subjects with Active Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 632

Long-Term Golimumab Retention Rate in Patients with Psoriatic Arthritis. Is Concomitant DMARD Important?

9:00AM-11:00AM: Abstract Number: 582

Low Dose Computed Tomography Detects More Progression of Bone Formation in Comparison to Conventional Radiography in Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 600

Low Rates of Major Adverse Cardiac Events, Malignancies, and Serious Infections in Subjects with Psoriasis and Psoriatic Arthritis Treated with Apremilast for ≥156 Weeks: Pooled Analysis from the Esteem and Palace 1-3 Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 631

Predictors of Long-Term Retention of Methotrexate and Other Dmards with Golimumab in Rheumatoid Arthritis and Psoriatic Arthritis: An Analysis from a Prospective, Observational Registry

9:00AM-11:00AM: Abstract Number: 608

Presence of Poor Prognostic Factors May Predict Response to Abatacept in Patients with Active Psoriatic Arthritis: Results from a Post Hoc Analysis from a Phase III Study

9:00AM-11:00AM: Abstract Number: 593

Progression of Structural Damage on MRI in Patients with Axial Spondyloarthritis Is Limited: The 5 –Year Results in the DESIR Cohort

9:00AM-11:00AM: Abstract Number: 626

Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks

9:00AM-11:00AM: Abstract Number: 625

Rapid Onset of Efficacy in Patients with Active Psoriatic Arthritis Treated with Ixekizumab: A Pooled Analysis of Data from Two Phase III Clinical Trials

9:00AM-11:00AM: Abstract Number: 612

Safety and Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis over a 6 Month Period

9:00AM-11:00AM: Abstract Number: 620

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open‑Label, Long-Term Extension Study

9:00AM-11:00AM: Abstract Number: 606

Secukinumab Demonstrates Consistent Safety over Long-Term Exposure in Patients with Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses

9:00AM-11:00AM: Abstract Number: 621

Secukinumab Provides Sustained Improvement in Major and Moderate Response of Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study

9:00AM-11:00AM: Abstract Number: 622

Secukinumab Provides Sustained Minimal Disease Activity (MDA) and Remission Related to Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study

9:00AM-11:00AM: Abstract Number: 618

Secukinumab Sustains Individual Clinical Responses over Time in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 3 Trial

9:00AM-11:00AM: Abstract Number: 607

Secukinumab Treatment of Psoriatic Arthritis and Moderate to Severe Psoriasis Relieves Anxiety/Depression up to 52 Weeks: An Overview from Secukinumab Phase 3 Clinical Trials

9:00AM-11:00AM: Abstract Number: 635

Short-Term Efficacy and Safety of New Biological Agents Targeting the IL-6, IL-12/23 and IL-17 Pathways for Active Psoriatic Arthritis: A Network Meta-Analysis of Randomised Controlled Trials

9:00AM-11:00AM: Abstract Number: 580

Tenascin-C, a TLR 4 Endogenous Ligand Levels Are Increased in Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 637

The Effect of Biologic Therapies on the Gut Microbial Composition in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 577

The Value of C-Reactive Protein As a Predictor of Radiographic Spinal Progression Is Strongly Dependent on β-Fibrinogen and Factor XIII a-Subunit Genotypes in Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 623

Tofacitinib Improves Composite Endpoint Measures of Disease in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 586

Validation of Online Calibration Modules for the Spondyloarthritis Research Consortium of Canada MRI Scores Based on Real-Time Experiential Learning

9:00AM-11:00AM: Abstract Number: 592

Which Imaging Outcomes for AxSpA Are Most Sensitive to Change? a 5-Year Analysis of the DESIR Cohort

9:00AM-11:00AM: Abstract Number: 590

X-Ray Spine Lesions Are Rare and Not Discriminant for Axial Spondyloarthritis Recognition in Patients with Recent Onset Chronic Back Pain

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].